ACTUATE THERAPEUTICS ($ACTU) posted quarterly earnings results for Q3 2026 on Friday, November 13th. The company reported earnings of -$0.14 per share, beating estimates of -$0.17 by $0.03. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $ACTU stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ACTUATE THERAPEUTICS Insider Trading Activity
ACTUATE THERAPEUTICS insiders have traded $ACTU stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ACTU stock by insiders over the last 6 months:
- DANIEL M SCHMITT (President, CEO and Director) purchased 140,844 shares for an estimated $49,999
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
ACTUATE THERAPEUTICS Hedge Fund Activity
We have seen 13 institutional investors add shares of ACTUATE THERAPEUTICS stock to their portfolio, and 51 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AQR CAPITAL MANAGEMENT LLC added 100,384 shares (+370.3%) to their portfolio in Q2 2026, for an estimated $153,587
- MILLENNIUM MANAGEMENT LLC added 96,684 shares (+inf%) to their portfolio in Q2 2026, for an estimated $147,926
- NORTHERN TRUST CORP removed 76,631 shares (-78.3%) from their portfolio in Q2 2026, for an estimated $117,245
- JANE STREET GROUP, LLC removed 39,132 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $30,511
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 28,182 shares (+inf%) to their portfolio in Q2 2026, for an estimated $43,118
- EMPOWERED FUNDS, LLC added 23,106 shares (+inf%) to their portfolio in Q3 2026, for an estimated $18,015
- BLACKROCK, INC. removed 23,091 shares (-25.6%) from their portfolio in Q3 2026, for an estimated $18,004
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
ACTUATE THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $ACTU in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 08/18/2026
- Rodman & Renshaw issued a "Buy" rating on 07/30/2026
To track analyst ratings and price targets for ACTUATE THERAPEUTICS, check out Quiver Quantitative's $ACTU forecast page.
ACTUATE THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $ACTU recently. We have seen 2 analysts offer price targets for $ACTU in the last 6 months, with a median target of $10.5.
Here are some recent targets:
- Swayampakula Ramakanth from HC Wainwright & Co. set a target price of $15.0 on 08/18/2026
- Michael G. King Jr. from Rodman & Renshaw set a target price of $6.0 on 07/30/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
